{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:29:56Z","timestamp":1790198996846,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T00:00:00Z","timestamp":1727568000000},"content-version":"am","delay-in-days":394,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clinthera.2023.07.002","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T08:35:34Z","timestamp":1690014934000},"page":"889-893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association Between Risperidone Use and Kidney Function Decline in Patients with Schizophrenia: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-5229","authenticated-orcid":false,"given":"Megumi","family":"Oshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Yomogida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichirou","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.07.002_bib0001","unstructured":"United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD."},{"key":"10.1016\/j.clinthera.2023.07.002_bib0002","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0003","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97957","article-title":"Gut microbiota-derived D-serine protects against acute kidney injury","volume":"3","author":"Nakade","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0005","doi-asserted-by":"crossref","first-page":"F667","DOI":"10.1152\/ajprenal.00198.2021","article-title":"Protective effect of d-alanine against acute kidney injury","volume":"322","author":"Iwata","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0006","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.34067\/KID.0000832021","article-title":"d-Serine mediates cellular proliferation for kidney remodeling","volume":"2","author":"Hesaka","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0007","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1016\/j.jchromb.2010.08.024","article-title":"Simultaneous two-dimensional HPLC determination of free D-serine and D-alanine in the brain and periphery of mutant rats lacking D-amino-acid oxidase","volume":"879","author":"Miyoshi","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0008","doi-asserted-by":"crossref","first-page":"16125","DOI":"10.1038\/nmicrobiol.2016.125","article-title":"Interplay between microbial d-amino acids and host d-amino acid oxidase modifies murine mucosal defence and gut microbiota","volume":"1","author":"Sasabe","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0009","doi-asserted-by":"crossref","first-page":"21773","DOI":"10.1038\/s41598-022-26175-1","article-title":"Increased levels of oral Streptococcus-derived D-alanine in patients with chronic kidney disease and diabetes mellitus","volume":"12","author":"Nakade","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0010","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.34067\/KID.0004282021","article-title":"Identification of diabetic nephropathy in patients undergoing kidney biopsy through blood and urinary profiles of d-serine","volume":"2","author":"Iwata","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0011","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10157-021-02052-5","article-title":"Intra-body dynamics of D-serine reflects the origin of kidney diseases","volume":"25","author":"Okushima","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.07.002_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.10075su1.01","article-title":"Antipsychotics in the treatment of schizophrenia: an overview","volume":"72","author":"Tandon","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0013","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5582\/bst.2014.01034","article-title":"Evaluation of human D-amino acid oxidase inhibition by anti-psychotic drugs in vitro","volume":"8","author":"Shishikura","year":"2014","journal-title":"Biosci Trends"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lfs.2016.06.021","article-title":"Effect of risperidone on plasma d-serine concentration in rats post-administered with d-serine","volume":"158","author":"Onozato","year":"2016","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/0269881109102644","article-title":"The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia","volume":"24","author":"Abou El-Magd","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0016","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"D-serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"Tsai","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0017","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.febslet.2006.03.045","article-title":"Characterization of human D-amino acid oxidase","volume":"580","author":"Molla","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0018","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0019","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","article-title":"Report of the committee on the classification and diagnostic criteria of diabetes mellitus","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0021","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40263-017-0421-4","article-title":"A retrospective cohort study of acute kidney injury risk associated with antipsychotics","volume":"31","author":"Jiang","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0023","doi-asserted-by":"crossref","first-page":"242","DOI":"10.7326\/M13-2796","article-title":"Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study","volume":"161","author":"Hwang","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0024","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-022-03339-6","article-title":"Incidence of hospital contacts with acute kidney injury after initiation of second-generation antipsychotics in older adults: a Danish population-based cohort study","volume":"78","author":"Sharon","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/gps.1446","article-title":"A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration","volume":"21","author":"Ritchie","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jpba.2015.05.024","article-title":"Simultaneous analysis of D-alanine, D-aspartic acid, and D-serine using chiral high-performance liquid chromatography-tandem mass spectrometry and its application to the rat plasma and tissues","volume":"115","author":"Karakawa","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0027","doi-asserted-by":"crossref","first-page":"26137","DOI":"10.1038\/srep26137","article-title":"Chiral amino acid metabolomics for novel biomarker screening in the prognosis of chronic kidney disease","volume":"6","author":"Kimura","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0028","doi-asserted-by":"crossref","first-page":"11569","DOI":"10.1021\/acs.analchem.9b01615","article-title":"Three-dimensional high-performance liquid chromatographic determination of Asn, Ser, Ala, and Pro enantiomers in the plasma of patients with chronic kidney disease","volume":"91","author":"Furusho","year":"2019","journal-title":"Anal Chem"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0029","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/17460441.2018.1524459","article-title":"Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies","volume":"13","author":"Szilagyi","year":"2018","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0030","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","article-title":"Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia","volume":"60","author":"Hashimoto","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2006.10.010","article-title":"A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia","volume":"90","author":"Bendikov","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0032","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"Heresco-Levy","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0033","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.4088\/JCP.11m07031","article-title":"A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia","volume":"73","author":"Weiser","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0034","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0035","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0b013e318297980e","article-title":"Weight gain in risperidone therapy: investigation of peripheral hypothalamic neurohormone levels in psychotic patients","volume":"33","author":"Yanik","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0036","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jamapsychiatry.2018.1088","article-title":"Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: a randomized clinical trial","volume":"75","author":"Nicol","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0037","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41386-021-01163-7","article-title":"Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis","volume":"47","author":"Stogios","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2023.07.002_bib0038","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrneph.2016.75","article-title":"Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis","volume":"12","author":"D'Agati","year":"2016","journal-title":"Nat Rev Nephrol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:59:23Z","timestamp":1758963563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823002527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0149291823002527"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.07.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Risperidone Use and Kidney Function Decline in Patients with Schizophrenia: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}